모든 사진(2)
About This Item
실험식(Hill 표기법):
C9H16ClN3O2
CAS Number:
Molecular Weight:
233.70
EC Number:
MDL number:
UNSPSC 코드:
12352100
PubChem Substance ID:
NACRES:
NA.25
추천 제품
생화학적/생리학적 작용
Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.
신호어
Danger
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Acute Tox. 3 Oral - Carc. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
개인 보호 장비
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
이미 열람한 고객
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Moritz Stuplich et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), e180-e183 (2012-06-13)
Roger J Packer et al.
Neuro-oncology, 15(1), 97-103 (2012-10-27)
The purpose of the trial was to determine the survival and incidence of secondary tumors in children with medulloblastoma receiving radiotherapy plus chemotherapy. Three hundred seventy-nine eligible patients with nondisseminated medulloblastoma between the ages of 3 and 21 years were
Autumn L Dutelle et al.
Journal of feline medicine and surgery, 14(10), 694-700 (2012-05-12)
This retrospective study evaluated the use of lomustine as a rescue agent for 39 cases of resistant feline lymphoma. Parameters assessed included lymphocyte cell size, number of previous chemotherapy drugs and number of previous chemotherapy protocols received, time from lymphoma
Thierry Gorlia et al.
European journal of cancer (Oxford, England : 1990), 49(16), 3477-3485 (2013-07-31)
The prognosis of patients with anaplastic oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable. Biomarkers might be helpful to identify more homogeneous disease subtypes and improve therapeutic index. The aim of this study is to develop new clinical, pathological and molecular
Enrico Franceschi et al.
Neuro-oncology, 14(12), 1503-1510 (2012-10-24)
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.